ES2233931T3 - Fenilacetato y derivados, solos o en combinacion con otros compuestos, contra estados neoplasicos y otros trastornos. - Google Patents

Fenilacetato y derivados, solos o en combinacion con otros compuestos, contra estados neoplasicos y otros trastornos.

Info

Publication number
ES2233931T3
ES2233931T3 ES94930694T ES94930694T ES2233931T3 ES 2233931 T3 ES2233931 T3 ES 2233931T3 ES 94930694 T ES94930694 T ES 94930694T ES 94930694 T ES94930694 T ES 94930694T ES 2233931 T3 ES2233931 T3 ES 2233931T3
Authority
ES
Spain
Prior art keywords
phenylacetate
methods
combination
derivatives
presented
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94930694T
Other languages
English (en)
Inventor
Dvorit Samid
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/135,661 external-priority patent/US5635532A/en
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Application granted granted Critical
Publication of ES2233931T3 publication Critical patent/ES2233931T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)

Abstract

SE PRESENTAN COMPOSICIONES Y METODOS PARA EL TRATAMIENTO DE DIFERENTES DESORDENES MEDIANTE LA ADMINISTRACION DE UNA CANTIDAD TERAPEUTICAMENTE EFECTIVA DE FENILACETATO O DE DERIVADOS FARMACOLOGICAMENTE ACEPTABLES DEL MISMO O DE DERIVADOS DEL MISMO SOLOS O EN COMBINACION O EN CONJUNCION CON OTROS AGENTES TERAPEUTICOS, INCLUYENDO RETINOIDES, HIDROXIUREA Y FLAVONOIDES. SE PRESENTAN METODOS INTRAVESICULA PARA EL TRATAMIENTO DEL FENILACETATO DE CANCERES. TAMBIEN SON ASPECTOS DE ESTA INVENCION SALES FARMACOLOGICAMENTE ACEPTABLES SOLAS O EN COMBINACION Y METODOS PARA EVITAR EL SIDA Y LAS CONDICIONES MALIGNAS, E INDUCIR LA DIFERENCIACION CELULAR. SE PRESENTA UN PRODUCTO COMO UNA PREPARACION COMBINADA DE FENILACETATO Y UN RETINOIDE, HIDROXIUREA O FLAVONOIDE (DIFERENTE DEL INHIBIDOR DE LA VIA DEL MEVALONATO) PARA SU USO EN EL TRATAMIENTO SIMULTANEO, SEPARADO O SECUENCIAL DE UNA CONDICION NEOPLASTICA EN UN SUJETO. TAMBIEN SE PRESENTAN METODOS PARA MODULAR EL METABOLISMO DE LOS LIPIDOS Y/O REDUCIR LOS TRIGLICERIDOS EN SANGRE EN UN SUJETO USANDO FENILACETATO.
ES94930694T 1993-10-12 1994-10-12 Fenilacetato y derivados, solos o en combinacion con otros compuestos, contra estados neoplasicos y otros trastornos. Expired - Lifetime ES2233931T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/135,661 US5635532A (en) 1991-10-21 1993-10-12 Compositions and methods for therapy and prevention of pathologies including cancer, AIDS and anemia
US08/207,521 US5605930A (en) 1991-10-21 1994-03-07 Compositions and methods for treating and preventing pathologies including cancer

Publications (1)

Publication Number Publication Date
ES2233931T3 true ES2233931T3 (es) 2005-06-16

Family

ID=26833540

Family Applications (2)

Application Number Title Priority Date Filing Date
ES94930694T Expired - Lifetime ES2233931T3 (es) 1993-10-12 1994-10-12 Fenilacetato y derivados, solos o en combinacion con otros compuestos, contra estados neoplasicos y otros trastornos.
ES04030912T Expired - Lifetime ES2303624T3 (es) 1993-10-12 1994-10-12 Fenilacetato y derivados solos o en combinacion con otros compuestos contra afecciones neoplasicas y otros trastornos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES04030912T Expired - Lifetime ES2303624T3 (es) 1993-10-12 1994-10-12 Fenilacetato y derivados solos o en combinacion con otros compuestos contra afecciones neoplasicas y otros trastornos.

Country Status (14)

Country Link
US (4) US5605930A (es)
EP (2) EP1523982B1 (es)
JP (5) JP3628694B2 (es)
AT (2) ATE388699T1 (es)
AU (1) AU702051B2 (es)
CA (1) CA2173976C (es)
DE (2) DE69435086T2 (es)
DK (1) DK1523982T3 (es)
ES (2) ES2233931T3 (es)
IL (1) IL111251A (es)
NZ (1) NZ275673A (es)
PT (2) PT725635E (es)
SI (1) SI1523982T1 (es)
WO (1) WO1995010271A2 (es)

Families Citing this family (117)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6204370B1 (en) * 1992-03-11 2001-03-20 Institute Of Virology, Slovak Academy Of Sciences MN gene and protein
US6407082B1 (en) 1996-09-13 2002-06-18 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of a vitamin D compound
RO115498B1 (ro) * 1993-10-29 2000-03-30 Univ Boston Metoda de tratament a neoplasmului
US5981597A (en) * 1995-02-13 1999-11-09 Trustees Of The University Of Pennsylvania Differentiating agents for the treatment of inflammatory intestinal diseases
US5705352A (en) * 1995-02-27 1998-01-06 Eli Lilly And Company Multiple drug resistance gene of Aspergillus fumigatus
US5932619A (en) * 1995-10-13 1999-08-03 Rush-Presbyterian, St. Luke's Medical Center Method for preventing sexually transmitted diseases
JP2000511670A (ja) * 1996-06-11 2000-09-05 イェン クァン オゥン 反復的問題解決技術
US6197743B1 (en) 1996-07-26 2001-03-06 The Trustees Of Boston University Compositions and methods for the treatment of viral disorders
EP1886677A1 (en) * 1996-07-26 2008-02-13 Susan P. Perrine Use of an inducing agent for the treatment of blood, viral and cellular disorders
DE69726182T2 (de) 1996-12-11 2004-08-12 Dana-Farber Cancer Institute, Inc., Boston Methoden und pharmazeutische zusammenstellungen zur wachstumsverhinderung von tumorzellen enthaltend einen ppar-gamma agonisten und einen map kinase inhibitor
IL131628A0 (en) * 1997-03-04 2001-01-28 Wisconsin Alumni Res Found Method of suppressing tumor growth with combinations of isoprenoids and statins
US6110955A (en) * 1997-03-11 2000-08-29 Beacon Laboratories, Inc. Metabolically stabilized oxyalkylene esters and uses thereof
US5939455A (en) * 1997-03-11 1999-08-17 Beacon Laboratories, Inc. Therapeutic augmentation of oxyalkylene diesters and butyric acid derivatives
ES2312184T3 (es) * 1997-03-21 2009-02-16 Chugai Seiyaku Kabushiki Kaisha Agentes preventivos terapeuticos para el tratamiento de esclerosis multiple, que contienen anticuerpos anti-receptores de il-6 antagonistas.
DE69827138T2 (de) * 1997-08-11 2006-02-23 Allergan, Inc., Irvine Steriles Retinoid enthaltendes biodegradierbares Implantat mit verbesserter Biokompatibilität und Verfahren zu dessen Herstellung
US6242196B1 (en) 1997-12-11 2001-06-05 Dana-Farber Cancer Institute Methods and pharmaceutical compositions for inhibiting tumor cell growth
CA2324426A1 (en) * 1998-02-11 1999-08-19 Douglas V. Faller Compositions and methods for the treatment of cystic fibrosis
US6258849B1 (en) * 1998-07-23 2001-07-10 Stanislaw R. Burzynski Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate
WO2000018394A1 (en) * 1998-09-28 2000-04-06 The Johns Hopkins University Adrenoleukodystrophy treatments and drug screening
US6127419A (en) * 1998-11-23 2000-10-03 Burzynski; Stanislaw R. Phenylacetic acid compositions for treating or preventing atherosclerosis and restenosis
EP1137427A1 (en) * 1998-12-07 2001-10-04 Ecosmart Technologies Inc. Cancer treatment composition and method using natural plant essential oils with signal transduction modulators
EP1162884A4 (en) * 1999-03-19 2002-07-24 Vertex Pharma LOW-DOSE ORAL COMPOSITIONS OF BUTYRATE COMPOSITIONS
WO2000067737A2 (en) * 1999-05-07 2000-11-16 The Brigham And Women's Hospital, Inc. USE OF HMGCoA REDUCTASE INHIBITORS IN THE PREVENTION OF DISEASES WHOSE PATHOGENESIS IS DEPENDENT ON NEOVASCULARIZATION
US6624194B1 (en) * 1999-06-04 2003-09-23 Metabolex, Inc. Use of (−) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia
US6262118B1 (en) 1999-06-04 2001-07-17 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia
US7576131B2 (en) * 1999-06-04 2009-08-18 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia
US6403646B1 (en) 1999-06-30 2002-06-11 David H. Perlmutter Method for the treatment of alpha-1-antitrypsin deficiency and related pathologies
US6733779B2 (en) * 1999-08-26 2004-05-11 L. Dean Parks Method of treating benign prostatic hyperplasia and other benign prostate conditions
US6458838B1 (en) * 1999-09-28 2002-10-01 Johns Hopkins University Adrenoleukodystrophy treatments
US6864355B1 (en) 2000-05-02 2005-03-08 Yale University Inhibition of NF-κB activation by blockade of IKKβ-NEMO interactions at the NEMO binding domain
US6534537B2 (en) * 2000-01-07 2003-03-18 Kenneth Weisman Use of HMG-COA reductase inhibitors to prevent and treat BPH
US6723506B2 (en) 2000-01-20 2004-04-20 Brigham And Women's Hospital Method of identifying PAX8-PPAR gamma-nucleic acid molecules
AU2001243515A1 (en) * 2000-03-08 2001-09-17 Rhode Island Hospital, A Lifespan Partner Combination drug therapy
US6987131B1 (en) * 2000-06-26 2006-01-17 Burzynski Stanislaw R Phenylacetic acid compositions for treating or preventing hypercholesterolemia
EP1642885B1 (en) 2000-08-29 2009-11-11 Biocon Limited Use of a pharmaceutical composition containing a para-aminophenyl acetic acid derivative for treating inflammatory conditions of the gastrointestinal tract
US6538030B2 (en) 2000-09-20 2003-03-25 Yih-Lin Chung Treating radiation fibrosis
WO2002044419A2 (en) 2000-11-28 2002-06-06 Wyeth Expression analysis of kiaa nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
US6821731B2 (en) * 2000-11-28 2004-11-23 Wyeth Expression analysis of FKBP nucleic acids and polypeptides useful in the diagnosis of prostate cancer
HUP0303899A3 (en) * 2000-11-28 2007-05-02 Wyeth Corp Expression analysis of smarc nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
US7033611B2 (en) * 2001-02-23 2006-04-25 Biora Bioex Ab Matrix protein compositions for guided connective tissue growth
US6495719B2 (en) 2001-03-27 2002-12-17 Circagen Pharmaceutical Histone deacetylase inhibitors
US7312247B2 (en) 2001-03-27 2007-12-25 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors
US7842727B2 (en) * 2001-03-27 2010-11-30 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors
US8026280B2 (en) 2001-03-27 2011-09-27 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors
US8048924B2 (en) 2001-08-29 2011-11-01 Biocon Limited Methods and compositions employing 4-aminophenylacetic acid compounds
EP1291015A1 (en) 2001-09-10 2003-03-12 Lunamed AG Dosage forms having prolonged active ingredient release
MY131170A (en) * 2002-03-28 2007-07-31 Nissan Chemical Ind Ltd Therapeutic agent for glomerular disease
DE10313900A1 (de) * 2002-04-10 2003-10-30 Haemato Basics Gmbh Vitamin-Kombination zum Schutz bei Chemo- oder/ und Strahlungstherapie maligner Tumoren
US20040229948A1 (en) * 2002-04-12 2004-11-18 Summar Marshall L. Method for preventing hepatic encephalopathic episodes
US8946295B2 (en) * 2002-07-25 2015-02-03 Sunny Pharmtech Inc. Histone hyperacetylating agents for promoting wound healing and preventing scar formation
US8846039B2 (en) * 2002-04-26 2014-09-30 Asan Laboratories Company (Cayman), Limited Method for ameliorating pruritus
US20060275370A1 (en) * 2002-07-25 2006-12-07 Yih-Lin Chung Method and compositions for treatment of epithelial damage
US6809118B2 (en) * 2002-07-25 2004-10-26 Yih-Lin Chung Methods for therapy of radiation cutaneous syndrome
US8163764B2 (en) * 2002-04-26 2012-04-24 Asan Laboratories Company (Cayman) Limited Skincare methods
US20030206946A1 (en) * 2002-04-26 2003-11-06 Yih-Lin Chung Methods for therapy of connective tissue disease
US8883148B2 (en) * 2002-04-26 2014-11-11 Asan Laboratories Company (Cayman), Limited Prevention of joint destruction
WO2003093798A1 (en) * 2002-05-03 2003-11-13 Thomas Jefferson University Method to follow progression of kidney disease
GB0210741D0 (en) * 2002-05-10 2002-06-19 Medical Res Council Methods of therapy
WO2003099272A1 (en) * 2002-05-22 2003-12-04 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors based on alpha-ketoepoxide compounds
US7115563B2 (en) * 2002-05-29 2006-10-03 Insignion Holding Limited Composition and its therapeutic use
JP2006508986A (ja) * 2002-11-20 2006-03-16 エルラント ゲネ セラペウチクス エルエルシー ヒストンデアセチラーゼ阻害剤による肺細胞の治療方法
US7199259B2 (en) * 2003-06-20 2007-04-03 Metabolex, Inc. Resolution of α-(phenoxy)phenylacetic acid derivatives
US20050100537A1 (en) * 2003-11-10 2005-05-12 Evans Gregory S. Methods and kits for reducing cellular damage, inhibiting free radical production, and scavenging free radicals in mammals
US20050182122A1 (en) * 2003-11-20 2005-08-18 Bello Carlo L. Method of treating abnormal cell growth using indolinone compounds
AR048210A1 (es) * 2003-12-19 2006-04-12 Chugai Pharmaceutical Co Ltd Un agente preventivo para la vasculitis.
TWI297606B (en) * 2004-01-16 2008-06-11 Nat Health Research Institutes Cancer therapy
ES2410587T3 (es) 2004-01-22 2013-07-02 University Of Miami Formulaciones tópicas de coenzima Q10 y métodos de uso
AU2005208990A1 (en) * 2004-01-28 2005-08-11 Androscience Corporation Enhancement of anti-androgenic activity by a combination of inhibitors targeting different steps of a steroid-dependent gene activation pathway and uses thereof
US20060084704A1 (en) * 2004-01-28 2006-04-20 Charles Shih Methods and compositions for enhancing degradation of nuclear receptor transcription factors and uses thereof
WO2005079849A2 (en) * 2004-02-25 2005-09-01 Zgene A/S Compounds for enhanced cancer therapy
WO2005115384A2 (en) * 2004-05-25 2005-12-08 Metabolex, Inc. Bicyclic, substituted triazoles as modulators of ppar and methods of their preparation
AU2005247473A1 (en) * 2004-05-25 2005-12-08 Metabolex, Inc. Substituted triazoles as modulators of PPAR and methods of their preparation
HUE028158T2 (en) 2004-07-07 2016-12-28 Biocon Ltd Synthesis of bound immunoregulatory compounds
US20060073213A1 (en) * 2004-09-15 2006-04-06 Hotamisligil Gokhan S Reducing ER stress in the treatment of obesity and diabetes
EP1799263A4 (en) * 2004-09-15 2009-07-29 Harvard College REDUCTION OF ER-STRESS IN THE TREATMENT OF ADIPOSITAS AND DIABETES
EP1817020A4 (en) * 2004-11-08 2012-11-21 Errant Gene Therapeutics Inc INHIBITORS OF HISTONATE ACETYLASE
US8377918B2 (en) * 2005-01-31 2013-02-19 ACC Therapeutics Inc Apigenin for chemoprevention, and chemotherapy combined with therapeutic reagents
US7666676B2 (en) * 2005-05-16 2010-02-23 St. Joseph's Children's Hospital Modulating cancer cell characteristics
CA2619568A1 (en) * 2005-08-19 2007-03-01 Government Of The United States Of America, Represented By The Secretary , Department Of Health And Human Services Topical formulations of histone deacetylase inhibitors and methods of using the same
US7714131B2 (en) * 2005-09-23 2010-05-11 Metabolex, Inc. Process for the stereoselective preparation of (−)-halofenate and derivatives thereof
KR100745821B1 (ko) * 2005-09-23 2007-08-02 에스케이 주식회사 소디움 페닐부티레이트를 이용한 약물 또는 알코올 중독,또는 조울증의 예방 및 치료용 의약 조성물
US8710272B2 (en) 2007-01-08 2014-04-29 Androscience Corporation Compounds with (1 E, 6E)-1,7-bis-(3,4-dimethoxyphenyl)-4,4-disubstituted-hepta-1,6-diene-3,5-dione structural scaffold, their biological activity, and uses thereof
CN101711231B (zh) 2007-01-08 2014-03-12 安德鲁科技有限公司 具有(取代苯基)-丙烯醛部分的化合物、它们的衍生物、生物活性及其用途
US9000222B2 (en) 2007-01-08 2015-04-07 Androscience Corporation Compounds with (1E, 6E)-1,7-bis-(3,4-dimethoxyphenyl)-4,4-disubstituted-hepta-1,6-diene-3,5-dione structural scaffold, their biological activity, and uses thereof
MX2009008247A (es) * 2007-02-05 2009-08-12 Wisconsin Alumni Res Found Biomarcadores de respuesta a la radiacion ionizante.
KR20100051808A (ko) 2007-07-31 2010-05-18 앤드로사이언스 코포레이션 안드로겐 수용체 분해 강화제를 포함한 조성물 및 탈모와 피부질환의 예방 또는 치료 방법
JP2009078977A (ja) * 2007-09-25 2009-04-16 Japan Health Science Foundation 心筋の小胞体ストレス抑制剤
CN101959429B (zh) 2008-01-08 2014-09-10 阿克塞利亚制药公司 抗微生物肽系统的激动剂
WO2009126764A1 (en) 2008-04-11 2009-10-15 Cytotech Labs, Llc Methods and use of inducing apoptosis in cancer cells
US9063122B2 (en) * 2008-10-17 2015-06-23 Alfredo Gallegos Biomodulators for treatment or prevention of disease
WO2010105112A1 (en) * 2009-03-11 2010-09-16 Hemaquest Pharmaceuticals, Inc. Detection of short-chain fatty acids in biological samples
WO2010120931A2 (en) * 2009-04-14 2010-10-21 University Of Medicine And Dentistry Of New Jersey E2f as a target for treatment of hormone refractory prostate cancer
MX2011011757A (es) * 2009-05-04 2012-01-25 Prometic Biosciences Inc Compuestos aromaticos substituidos y usos farmaceuticos.
EA023913B1 (ru) 2009-05-11 2016-07-29 БЕРГ ФАРМА ЭлЭлСи Способы лечения метаболических нарушений, использующие эпиметаболические переключатели, многоаспектные внутриклеточные молекулы или факторы влияния
US20110086869A1 (en) 2009-09-24 2011-04-14 The Trustees Of Boston University Methods for treating viral disorders
US8618068B2 (en) 2009-12-08 2013-12-31 Trustees Of Boston University Methods and low dose regimens for treating red blood cell disorders
US20110245154A1 (en) 2010-03-11 2011-10-06 Hemaquest Pharmaceuticals, Inc. Methods and Compositions for Treating Viral or Virally-Induced Conditions
EA035494B1 (ru) * 2010-10-27 2020-06-25 Прометик Фарма Смт Лимитед Способ и применение композиции для ингибирования миграции клеток опухоли и образования метастазов
CN103608323B (zh) 2011-04-04 2016-08-17 博格有限责任公司 治疗中枢神经系统肿瘤的方法
EP2599767A1 (en) 2011-11-30 2013-06-05 Lunamed AG Phenylbutyl-derivatives
EP2599482A1 (en) 2011-11-30 2013-06-05 Lunamed AG Low dose therapeutic use of glyceryl tri-(4-phenylbutyrate)
EP2607367A1 (en) 2011-12-21 2013-06-26 Lunamed AG Glycerol phenyl butyrate derivatives
EP2607366A1 (en) 2011-12-21 2013-06-26 Lunamed AG Glycerol phenyl butyrate esters
WO2013170756A1 (zh) * 2012-05-15 2013-11-21 北京京朋汇药业研究发展有限公司 高原儿茶酸在制备抗肿瘤药物中的用途
EP2716167A1 (en) * 2012-10-02 2014-04-09 Lunamed AG Non-pharmaceutical composition comprising short chain fatty acids
WO2014138391A1 (en) * 2013-03-06 2014-09-12 The Johns Hopkins University Targeting glutamine metabolism in brain tumors
EP2983654B1 (en) 2013-04-08 2025-11-12 BPGbio, Inc. Treatment of cancer using coenzyme q10 combination therapies
WO2015035094A1 (en) 2013-09-04 2015-03-12 Berg Llc Methods of treatment of cancer by continuous infusion of coenzyme q10
US20170189350A1 (en) 2015-11-16 2017-07-06 Berg Llc Methods of treatment of temozolomide-resistant glioma using coenzyme q10
JP7373991B2 (ja) 2016-07-15 2023-11-06 ビラクタ セラピューティクス，インク． 免疫療法で使用するためのヒストン脱アセチル化酵素阻害剤
JP7136807B2 (ja) 2017-04-17 2022-09-13 ザ・ユニバーシティ・オブ・シカゴ ヒトの健康及び疾患の治療用途向けの短鎖脂肪酸の腸への送達用ポリマー材料
MX2021014639A (es) 2019-05-31 2022-04-06 Viracta Subsidiary Inc Metodos para tratar canceres asociados con virus con inhibidores de la histona deacetilasa.
US11633554B1 (en) * 2019-06-11 2023-04-25 Luca Puviani Adaptive systems and methods for delivery of a medicament
KR102135026B1 (ko) * 2019-11-22 2020-07-17 한국지질자원연구원 시계열 지표수 흐름 거동 예측방법
CN114184693B (zh) * 2021-10-14 2023-10-13 重庆医科大学 4-羟苯乙酸作为标志物在制备脓毒症脑病的诊断试剂盒中的应用
EP4661859A1 (en) 2023-02-10 2025-12-17 Ludwig-Maximilians-Universität München, in Vertretung des Freistaates Bayern Oral phenylbutyrate for treatment of human 4-repeat tauopathies
WO2024256849A1 (en) 2023-06-13 2024-12-19 Phenotec Ag 4-phenylbutyric acid derivatives for use in the treatment of fibrosis

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4028404A (en) * 1967-07-31 1977-06-07 Allen & Hanburys Limited Acetic acid derivatives
US3998966A (en) * 1971-11-04 1976-12-21 Syntex Corporation Anti-inflammatory, analgesic, anti-pyretic and anti-pruritic 6-substituted 2-naphthyl acetic acid derivative-containing compositions and methods of use thereof
CH576445A5 (es) * 1972-03-10 1976-06-15 Ciba Geigy Ag
US3976673A (en) * 1974-01-14 1976-08-24 Isf Spa 4-Cyclopropylmethyleneoxy-3-chlorophenylacetic acid and salts thereof
GB1511645A (en) * 1974-05-31 1978-05-24 Univ Ife Sickle cell anaemia treatment
FR2416214A1 (fr) * 1978-02-02 1979-08-31 Inst Rech Scient Irs Derives d'acide naphtyl-1 acetique, leur procede de preparation et leur application therapeutique
US4282214A (en) * 1978-07-31 1981-08-04 The Procter & Gamble Company Phenylacetate anti-inflammatory composition
AU528532B2 (en) * 1978-12-18 1983-05-05 Mcniel Laboratories Acetaminophen analgesic potentiation
US4470970A (en) * 1981-07-02 1984-09-11 Burzynski Stanislaw R Purified antineoplaston fractions and methods of treating neoplastic disease
US4499299A (en) * 1981-12-30 1985-02-12 Ici Americas Inc. Pharmaceutically active phenylcarboxylic acid derivatives
JPS58194814A (ja) * 1982-05-11 1983-11-12 Nippon Shinyaku Co Ltd 免疫調節作用を有する薬剤
US4457942A (en) * 1982-08-20 1984-07-03 Brusilow Saul W Process for waste nitrogen removal
DE3440288C2 (de) * 1984-11-05 1987-03-12 Gergely, Gerhard, Dr.-Ing., Wien Pharmazeutische Zubereitung mit einem Gehalt an Ibuprofen sowie Verfahren zu ihrer Herstellung
EP0212746B1 (en) * 1985-08-16 1991-04-10 The Procter & Gamble Company Drug particles having constant release
GB8524421D0 (en) * 1985-10-03 1985-11-06 Boots Co Plc Therapeutic agents
GB8528195D0 (en) * 1985-11-15 1985-12-18 Boots Co Plc Therapeutic compositions
GB8606762D0 (en) * 1986-03-19 1986-04-23 Boots Co Plc Therapeutic agents
CH669523A5 (es) * 1986-06-25 1989-03-31 Mepha Ag
GB8623557D0 (en) * 1986-10-01 1986-11-05 Boots Co Plc Therapeutic agents
US4788220A (en) * 1987-07-08 1988-11-29 American Home Products Corporation (Del.) Pediatric ibuprofen compositions
US4999226A (en) * 1988-06-01 1991-03-12 Merrell Dow Pharmaceuticals Inc. Pharmaceutical compositions for piperidinoalkanol-ibuprofen combination
US5032384A (en) * 1989-01-27 1991-07-16 Block Drug Company, Inc. Compositions and method for the treatment of disease
US4975465A (en) * 1989-03-28 1990-12-04 American Home Products Corporation Orally administrable ibuprofen compositions
NZ234143A (en) * 1989-06-28 1991-10-25 Mcneil Ppc Inc Aqueous pharmaceutical suspension formulation for administering substantially insoluble pharmaceutical agents
GB8920693D0 (en) * 1989-09-13 1989-10-25 Nicholas Kiwi Pty Ltd Non-effervescent ibuprofen compositions
US5204367A (en) * 1990-02-16 1993-04-20 Harbor Branch Oceanographic Institution, Inc. Novel antiviral and anti-leukemia terpene hydroquinones and methods of use
US5244922A (en) * 1990-09-04 1993-09-14 Burzynski Stanislaw R Methods for treating viral infections
AU2804592A (en) * 1991-10-21 1993-05-21 Dvorit Samid Compositions and methods for therapy and prevention of cancer, aids, and anemia

Also Published As

Publication number Publication date
US5843994A (en) 1998-12-01
EP1523982A2 (en) 2005-04-20
EP1523982A3 (en) 2005-04-27
DE69435086T2 (de) 2009-03-19
CA2173976C (en) 2008-02-19
JP2003119130A (ja) 2003-04-23
EP0725635B1 (en) 2004-12-29
JP2001253821A (ja) 2001-09-18
CA2173976A1 (en) 1995-04-20
JPH09506079A (ja) 1997-06-17
JP3628694B2 (ja) 2005-03-16
EP0725635A1 (en) 1996-08-14
DK1523982T3 (da) 2008-07-14
ATE285760T1 (de) 2005-01-15
NZ275673A (en) 2000-09-29
PT725635E (pt) 2005-05-31
WO1995010271A3 (en) 1995-06-22
WO1995010271A2 (en) 1995-04-20
JP2005139209A (ja) 2005-06-02
JP2005139208A (ja) 2005-06-02
DE69434211T2 (de) 2005-12-15
PT1523982E (pt) 2008-06-25
SI1523982T1 (sl) 2008-10-31
AU7973794A (en) 1995-05-04
DE69434211D1 (de) 2005-02-03
US5883124A (en) 1999-03-16
US5605930A (en) 1997-02-25
DE69435086D1 (de) 2008-04-24
IL111251A0 (en) 1994-12-29
EP1523982B1 (en) 2008-03-12
HK1077204A1 (en) 2006-02-10
ATE388699T1 (de) 2008-03-15
IL111251A (en) 2004-06-20
AU702051B2 (en) 1999-02-11
ES2303624T3 (es) 2008-08-16
US5852056A (en) 1998-12-22

Similar Documents

Publication Publication Date Title
AR004700A1 (es) 1alfa, 26 dihidroxi-d-homo-vitamina d3, una composicion farmaceutica que la comprende, un procedimiento para su preparacion y el uso de los mismos en laelaboracion de un medicamento
MX9606521A (es) Inhibidores de trombina novedosos, preparacion y uso de los mismos.
ES2195175T3 (es) Preparacion farmaceutica que comprende acido eicosapentaenoico y/o acido estearidonico.
ES2190472T3 (es) Parche transdermico para la administracion de 17-deacetil norgestimato, solo o en combinacion con un estrogeno.
MX9700538A (es) Uso de droloxifeno y sus sales farmaceuticamente aceptables en la preparacion de remedios para las enfermedades cardiovasculares.
CA2173976A1 (en) Phenylacetate and derivatives alone or in combination with other compounds against neoplastic conditions and other disorders
MX9301348A (es) Nuevos compuestos que tienen actividad farmacologica, proceso para su preparacion y composicion farmaceutica que los comprende.
ECSP941104A (es) Derivados de 2,6 diaminopurina, procedimiento para su preparacion y composiciones farmaceuticas que los contienen
ES2169197T3 (es) Composicion farmaceutica que comprende una alcanoil l-carnitina en combinacion con un acido graso poliinsaturado de la serie omega-3 para la prevencion y el tratamiento de trastornos del metabolismo de los lipidos.
PT88985A (pt) Processo para a preparacao de composicoes farmaceuticas nasais e ou oftalmicas contendo azelastina
GEP20043237B (en) Pyrazoline Derivatives, Method for Their Preparation and Compositions Containing Them for Treatment of Diseases Mediated by Cyclooxygenase-2
CO4750836A1 (es) Nuevos medicamentos y utilizacion (1-metiletil)-8-azoniabiciclo-[3.2.1]octnao y su uso en pre- paraciones medicas
CO4340681A1 (es) Procedimientos de uso para la inhibicion de la perdida osea y la disminucion del colesterol en suero
ES2182161T3 (es) Utilizacion de derivados de pirimidina para la preparacion de un medicamento para la prevencion del cancer.
ES2080307T3 (es) Composiciones farmaceuticas.
ES2045182T3 (es) Substancias fisiologicamente activas, un proceso para la preparacion de las mismas y composiciones farmaceuticas que las contienen.
AR006401A1 (es) Compuestos de pirrolopirrolona, una composicion farmaceutica que los contiene, su uso en la fabricacion de un medicamento y en terapia, procesospara su preparación y compuestos intermediarios para dichos procesos.
MX9400037A (es) Composicion oftalmica para el tratamiento de glaucoma e hipertension ocular.
ES2253378T3 (es) Extractos de espermatofitos con actividad antineoplasica.
IT1170214B (it) Composizione farmaceutica per la cura delle arteriopatie periferiche
ES2193233T3 (es) Uso de amiodipina, una sal de la misma o felodipina en combinacion con un inhibidor ace en la fabricacion de un medicamento para el tratamiento de insuficiencia cardiaca conjuntiva no isquemica.
AR005860A1 (es) Compuestos heterociclicos aromaticos, composiciones farmaceuticas y cosmeticas que los contienen, y su utilización.
ES2020171T3 (es) Eteres de 1-bencil-3-hidroximetilindazol con 2-hidroxiacidos alifaticos.
IT1282736B1 (it) Uso di derivati del p-amminofenolo per preparare composizioni farmaceutiche utili nel trattamento di malattie neurodegenerative
FI883719A0 (fi) Kombination av pyrimidinderivat och retinoider som separata komponenter foer att inducera och stimulera haorvaext och reducera haorfall.